An interventional study of Bifidobacterium longum subsp. infantis i18 and Placebo in Allergy, Gastrointestinal Symptoms and Gut -Microbiota, sponsored by DiproBio (Shanghai) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 0 Months to 36 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by DiproBio (Shanghai) Co., Ltd. · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Hypersensitivity with a site in China — 9 open to participants now, 9 under way, none of them phase 3. Hypersensitivity · China.
Among the 34 studies in Hypersensitivity with a site in China, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 with no phase, and was the 34th registered.
1,058 studies on the registry are indexed under Hypersensitivity; 150 are open to participants now.
Browse Hypersensitivity studies →9 of the 34 studies in Hypersensitivity with a site in China are open now. Recruiting first, the newest first:
Qifeng Zhang · Sites in China, United States
Children's Hospital of Fudan University · Sites in China
Ages 1–18
Bo Wang,MD · Sites in China
Ages 18+
Min-Tze LIONG · Sites in China, Malaysia
Ages 0 mo–36 mo · Healthy volunteers
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 14–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.
This study: 0 Months to 36 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 455 is above the median of 73 across 691 interventional studies indexed under Hypersensitivity.
Median enrollment 188 across the 19 interventional studies, 180 across the 15 observational. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 34 have an industry lead sponsor. The 10 most frequent:
DiproBio (Shanghai) Co., Ltd. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
DiproBio (Shanghai) Co., Ltd. has 1 study filed under Hypersensitivity — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Hypersensitivity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effects of Bifidobacterium longum subsp. infantis i18 supplementation on symptoms, gut microbiota development, and overall health outcomes in healthy infants and young children in China.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-
For the Probiotic and Placebo Groups:
For the Observational Reference Group:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Bifidobacterium longum subsp. infantis i18
Dietary Supplement: Placebo
Bifidobacterium longum subsp. infantis i18 supplementation.
Matching placebo without the probiotic intervention
Number of participants with newly reported allergic symptoms (atopic dermatitis/eczema etc.) as assessed with the structured allergy symptom questionnaire
Time frame: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
Number of participants with newly reported respiratory symptoms (respiratory tract infection etc.) as assessed with the structured respiratory symptom questionnaire
Time frame: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
Number of participants with newly reported gastrointestinal symptoms (constipation etc.) as assessed with the structured gastrointestinal symptom questionnaire
Time frame: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
Feeding pattern as assessed with the structured feeding questionnaire
Time frame: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
Growth and nutritional status: body weight (kg), length/height (cm) and head circumference (cm) measured with a calibrated scale, infantometer/stadiometer and measuring tape, with age- and sex-adjusted Z-scores per WHO Child Growth Standards
Time frame: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
Gut microbiota composition and diversity: relative abundance (%), alpha diversity and beta diversity in faecal samples assessed by metagenomic sequencing.
Time frame: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), faecal samples collected at each scheduled study visit.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
Of 24 industry-sponsored interventional studies with no phase under Hypersensitivity, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 11. This study's planned 13 months is above that.
Counting every sponsor, half of 174 studies reached it within 20 months; a quarter within 5 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DiproBio (Shanghai) Co., Ltd. →